Left Ventricular Ejection Fraction clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
open to eligible people ages 18-85
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
at UC Davis UC Irvine UCSF
Last updated: